Sanofi India Ltd share price logo

Sanofi India Share Price

(SANOFI)

Small Cap

Healthcare Sector

Check the latest share price of Sanofi India, details on performance, fundamentals, analyst ratings, peer comparison, financials, company news, analysis, and shareholding pattern for informed investing decisions.

₹5950.5▲0.13%

as on 04:01PM, 02 May 2025

NSE

bell
The current prices are delayed by 15 mins, login to check live prices.

Sanofi India Performance

Get real-time share price information, day’s high and low, historical returns and market stats.

  • Day's Low

    Day's High

    ₹5,864.5
    Day's Price Range
    ₹6,024.5

  • 52 Week's Low

    52 Week's High

    ₹4,902
    52-Week Price Range
    ₹10,524.95
1 Month Return-0.88 %
3 Month Return+ 8.86 %
1 Year Return-31 %
Previous Close₹5,943.00
Open₹5,942.00
Volume13.74K
Upper Circuit₹7,131.50
Lower Circuit₹4,754.50
Market Cap₹13,704.00Cr

Sanofi India Fundamentals & Key Indicators

Check the fundamental ratios and key indicators of the company like P/E, P/B, PEG, Dividend yield etc.

Market Cap

₹13,704.00 Cr

Return on Equity (ROE)

47.15

PE Ratio (TTM)

33.16

Return on capital employed (ROCE)

47.94

Beta (LTM)

0.48

P/B Ratio

16.36

Dividend Yield

1.91

PEG Ratio

-0.4

EPS (TTM)

179.7

Sector

Pharmaceuticals

Technical Analysis

Bearish

View Technical Analysis

How to invest in Sanofi India

Investing in Sanofi India is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Sanofi India or SANOFI on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.

For example: You can buy 10 shares of Sanofi India or start an SIP based on the market price on each investment date.

You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Sanofi India with just a few clicks!

Sanofi India Valuation

Track how the P/E of Sanofi India has moved over time to understand valuation trends.

Sanofi India in the last 5 years

  • Overview

  • Trends

Lowest (0.00x)

December 29, 2023

Today (33.16x)

May 2, 2025

Industry (54.34x)

May 2, 2025

Highest (42.25x)

June 12, 2024

LowHigh

Today’s Price to Earnings Ratio: 33.16x

Analysts Recommendation on Sanofi India

Get updated buy, sell, and hold recommendations by analysts on Sanofi India.

based on 3 analysts

BUY

75.00%

Buy

0.00%

Hold

25.00%

Sell

75% of analysts recommend a 'BUY' rating for Sanofi India. Average target price of ₹6672.33

Source: S&P Global Market Intelligence

Analysts Forecast on Sanofi India

Get share price movements and forecasts by analysts on Sanofi India.

Sanofi India price forecast by 3 analysts

Upside of12.13%

High

₹7560

Target

₹6672.33

Low

₹5800

Sanofi India target price ₹6672.33, a slight upside of 12.13% compared to current price of ₹5950.5. According to 3 analysts rating.

Source: S&P Global Market Intelligence

Sanofi India Financials

Get the annual and quarterly financial summary of Sanofi India, including revenue, profit, loss and more.

Value in ₹ crore
DetailsQ'4 23Q'1 24Q'2 24Q'3 24Q'4 24
Revenue₹469.20Cr (-)₹510.80Cr (↑8.87%)₹463.50Cr (↓9.26%)₹524.00Cr (↑13.05%)₹514.90Cr (↓1.74%)
Net Income₹137.70Cr (-)₹136.60Cr (↓0.80%)₹103.20Cr (↓24.45%)₹82.20Cr (↓20.35%)₹91.30Cr (↑11.07%)
Net Profit Margin29.35% (-)26.74% (↓8.89%)22.27% (↓16.72%)15.69% (↓29.55%)17.73% (↑13.00%)
Value in ₹ crore
Details2021202220232024
Total Assets₹3,105.60Cr (-)₹2,112.50Cr (↓31.98%)₹1,752.50Cr (↓17.04%)₹1,645.40Cr (↓6.11%)
Total Liabilities₹880.00Cr (-)₹836.70Cr (↓4.92%)₹737.00Cr (↓11.92%)₹784.80Cr (↑6.49%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹611.10Cr (-)₹558.80Cr (↓8.56%)₹398.70Cr (↓28.65%)₹230.80Cr (↓42.11%)₹461.70Cr (↑100.04%)

Sanofi India Index Inclusions

BSE Healthcare

₹41,995.12

-0.51 (▲-216.2%)

S&P BSE 250 SmallCap

₹6,157.39

-0.1 (▲-6.03%)

BSE Small-Cap

₹47,365.54

-0.07 (▲-34.77%)

S&P BSE 400 MidSmallCap

₹11,047.95

-0.35 (▲-39.29%)

BSE 500

₹34,623.50

-0.05 (▲-16.85%)

Sanofi India Earnings and Dividends

View detailed summary of the earnings and dividend history of Sanofi India.

  • Sanofi India Ltd Earnings Results

    Sanofi India Ltd’s net profit fell -33.7% since last year same period to ₹91.30Cr in the Q3 2024-2025. On a quarterly growth basis, Sanofi India Ltd has generated 11.07% jump in its net profits since last 3-months.

    Read More about Earnings Results

  • Sanofi India Ltd Dividends February,2025

    In the quarter ending December 2024, Sanofi India Ltd has declared dividend of ₹117 - translating a dividend yield of 1.97%.

    Read More about Dividends

Sanofi India Shareholding Pattern

View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Sanofi India.

InvestorsHoldings %Quarterly Trend3M change
Promoter Holdings
60.4%
0.00
Foreign Institutions
5.57%
0.00
Mutual Funds
11.26%
0.00
Retail Investors
11.01%
0.00
Others
11.76%
0.00

Sanofi India vs Peers

Compare market cap, revenue, PE, and other key metrics of Sanofi India with its industry peers.

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
Sanofi India Ltd
Sanofi India Ltd
BUY₹13,704.00 Cr-5.22%0.52₹413 Cr₹2,013 Cr
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd
BUY₹71,009.90 Cr17.1%0.56₹3,168 Cr₹29,001 Cr
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd
HOLD₹89,112.08 Cr33.64%0.64₹3,854 Cr₹19,547 Cr
Abbott India Ltd
Abbott India Ltd
BUY₹65,290.63 Cr13.77%0.53NANA
Glaxosmithkline Pharmaceuticals Ltd
Glaxosmithkline Pharmaceuticals Ltd
BUY₹48,328.15 Cr18.54%0.56₹589 Cr₹3,453 Cr
See all

Sanofi India News & Key Events

Latest news and events at one place to help you take investing decisions in Sanofi India.

  • Sanofi Gains Approval for Beyfortus in India - 28 Apr, 2025

    Sanofi's Beyfortus has received marketing authorization approval in India, allowing for improved immunization access for children through a partnership with Dr. Reddy's.

  • Sanofi India Denies Rumors of Lantus Sale - 16 Apr, 2025

    Sanofi India has refuted claims regarding the sale or licensing of its insulin brand, Lantus, stating that the information is unfounded and incorrect. The company has no plans to divest its flagship product.

  • Sanofi India Initiates Sale of Insulin Brand Lantus - 15 Apr, 2025

    Sanofi India has begun the sale process for its insulin brand Lantus, reducing the asking price from Rs 3,000 crore to Rs 2,000 crore. Major players like Dr. Reddy's Laboratories and Glenmark are in discussions to acquire it. If the sale does not attract sufficient interest, Sanofi may consider licensing deals with local manufacturers. This move aligns with Sanofi's strategy to focus on patented drugs and expand its consumer healthcare division.

  • Sanofi India Declares Final Dividend of Rs 117 - 14 Apr, 2025

    Sanofi India announced a final dividend of Rs 117 per share for the fiscal year ending December 2024, with a record date set for April 25, 2025. This marks the first dividend declaration post-demerger. The company's share price closed at Rs 6210, reflecting a 13% return over the past year and 59% over two years.

  • Sanofi India MD Rodolfo Hrosz to Step Down - 09 Apr, 2025

    Sanofi India Managing Director Rodolfo Hrosz will resign effective April 30, 2025, to take another position within the Sanofi group. The board has accepted his resignation and will seek a successor.

  • Positive Outlook for Sanofi India Stock - 08 Apr, 2025

    Sanofi India Ltd shows positive traction with a recommendation to buy above ₹5,980 and target prices of ₹6,500-6,750. Key metrics indicate potential growth, though risks from global supply chain dependence remain.

  • Sanofi India Wins Court Approval for Export Rebate - 02 Apr, 2025

    Sanofi India Limited received Gujarat High Court approval for a refund claim of Rs. 83,74,925 for 2014. The court's decision requires the company to submit necessary documents for the rebate claim, but it is not expected to materially impact the company's financial or operational activities.

Insights on Sanofi India Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, SANOFI stock has moved up by 8.9%

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 11.05% to 11.26% in Mar 2025 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Divis Laboratories Ltd has given 54.5% return, outperforming this stock by 85.5%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Torrent Pharmaceuticals Ltd has given 141.8% return, outperforming this stock by 156.3%

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 60.40% of holdings in Mar 2025 quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 11.04% to 11.01% in Mar 2025 quarter

  • imgNEGATIVE IMPACT

    FII Holding Down

    img

    Foreign Institutions have decreased holdings from 5.63% to 5.57% in Mar 2025 quarter

About Sanofi India

Sanofi India Limited (formerly Aventis Pharma) is one of the leading multinational companies (MNCs) in the Indian Pharmaceutical Market. It produces medicines for diabetes, cardiology, thrombosis, epilepsy, allergies, infections, vitamins, central nervous system and antihistamines. Its top products - Lantus, Combiflam, Amaryl and Allegra - feature among the top 100 pharmaceutical brands in India. Sanofi India has 2 own manufacturing facilities in Goa and Ankleshwar in Gujarat and sells products through independent distributors, primarily in India. Sanofi and Hoechst GmbH are the major shareholders of Sanofi India Limited holding 60.4% of its paid-up share capital. In the past few decades, the company has gone through several transformations, launched numerous products and merged/acquired a joint venture and a subsidiary company. In 2020, Sanofi India closed the transaction of slump sale and transfer of its Ankleshwar manufacturing facility to Zentiva Private Limited. In 2021, Sanofi India sold its Nutraceuticals business on a going concern basis to Universal Nutriscience Private Limited for a consideration of ₹5,870 million.

Revenue: ₹514.90Cr as on December 2024 (Q4 24)
Net Profit: ₹91.30Cr as on December 2024 (Q4 24)
Listing date: 06 Dec, 1994
Chairperson Name: Aditya Narayan
OrganisationSanofi India Ltd
Headquarters
IndustryPharmaceuticals
E-voting on sharesClick here to vote

Indian Mutual Funds that own Sanofi India

Check out the Mutual Funds with significant holdings in Sanofi India.

FAQs

What is Sanofi India Ltd price today?

Sanofi India Ltd share price today stands at ₹5950.5, Open: ₹5942, Previous Close: ₹5943, High: ₹6024.5, Low: ₹5864.5, 52 Week High: ₹10524.95, 52 Week Low: ₹4902.

How to Buy Sanofi India Ltd Share in India?

  • Get a PAN card
  • Open a Demat account
  • Open a Trading account
  • Link your Demat account to your Trading account
  • Fund your Trading account
  • Place an order to buy Sanofi India Ltd shares

What are today's traded volumes of Sanofi India Ltd?

Today's traded volume of Sanofi India Ltd(SANOFI) is 13.74K.

What is today's market capitalisation of Sanofi India Ltd?

Today's market capitalisation of Sanofi India Ltd(SANOFI) is ₹13,704.00 Cr.

What is the 52 Week High and Low Range of Sanofi India Ltd?

Sanofi India Ltd (SANOFI)
Price
52 Week High
₹10524.95
52 Week Low
₹4902

How much percentage Sanofi India Ltd is down from its 52 Week High?

Sanofi India Ltd (SANOFI) share price is ₹5950.5. It is down -43.46% from its 52 Week High price of ₹10524.95

How much percentage Sanofi India Ltd is up from its 52 Week low?

Sanofi India Ltd (SANOFI) share price is ₹5950.5. It is up 21.39% from its 52 Week Low price of ₹4902